GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioSig Technologies Inc (NAS:BSGM) » Definitions » Piotroski F-Score

BioSig Technologies (BioSig Technologies) Piotroski F-Score : 3 (As of Apr. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is BioSig Technologies Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

BioSig Technologies has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for BioSig Technologies's Piotroski F-Score or its related term are showing as below:

BSGM' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 3   Max: 4
Current: 3

During the past 11 years, the highest Piotroski F-Score of BioSig Technologies was 4. The lowest was 3. And the median was 3.


BioSig Technologies Piotroski F-Score Historical Data

The historical data trend for BioSig Technologies's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioSig Technologies Piotroski F-Score Chart

BioSig Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 3.00 4.00 3.00 3.00

BioSig Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 3.00 2.00 3.00

Competitive Comparison of BioSig Technologies's Piotroski F-Score

For the Medical Devices subindustry, BioSig Technologies's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioSig Technologies's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioSig Technologies's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where BioSig Technologies's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -7.332 + -11.093 + -4.567 + -6.049 = $-29.04 Mil.
Cash Flow from Operations was -5.648 + -4.895 + -3.828 + -2.942 = $-17.31 Mil.
Revenue was 0.005 + 0 + 0.001 + 0.012 = $0.02 Mil.
Gross Profit was 0.005 + 0 + 0.001 + 0.012 = $0.02 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(4.11 + 5.197 + 4.05 + 3.154 + 1.798) / 5 = $3.6618 Mil.
Total Assets at the begining of this year (Dec22) was $4.11 Mil.
Long-Term Debt & Capital Lease Obligation was $0.10 Mil.
Total Current Assets was $0.53 Mil.
Total Current Liabilities was $4.58 Mil.
Net Income was -7.963 + -5.759 + -6.372 + -6.958 = $-27.05 Mil.

Revenue was 0.008 + 0.008 + 0.135 + 0.135 = $0.29 Mil.
Gross Profit was 0.008 + 0.008 + 0.105 + 0.108 = $0.23 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(15.519 + 12.542 + 9.59 + 5.015 + 4.11) / 5 = $9.3552 Mil.
Total Assets at the begining of last year (Dec21) was $15.52 Mil.
Long-Term Debt & Capital Lease Obligation was $0.45 Mil.
Total Current Assets was $1.13 Mil.
Total Current Liabilities was $3.26 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

BioSig Technologies's current Net Income (TTM) was -29.04. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

BioSig Technologies's current Cash Flow from Operations (TTM) was -17.31. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-29.041/4.11
=-7.06593674

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-27.052/15.519
=-1.74315355

BioSig Technologies's return on assets of this year was -7.06593674. BioSig Technologies's return on assets of last year was -1.74315355. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

BioSig Technologies's current Net Income (TTM) was -29.04. BioSig Technologies's current Cash Flow from Operations (TTM) was -17.31. ==> -17.31 > -29.04 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0.103/3.6618
=0.02812824

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=0.452/9.3552
=0.04831538

BioSig Technologies's gearing of this year was 0.02812824. BioSig Technologies's gearing of last year was 0.04831538. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=0.528/4.582
=0.11523352

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=1.128/3.261
=0.34590616

BioSig Technologies's current ratio of this year was 0.11523352. BioSig Technologies's current ratio of last year was 0.34590616. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

BioSig Technologies's number of shares in issue this year was 8.684. BioSig Technologies's number of shares in issue last year was 5.135. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.018/0.018
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.229/0.286
=0.8006993

BioSig Technologies's gross margin of this year was 1. BioSig Technologies's gross margin of last year was 0.8006993. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=0.018/4.11
=0.00437956

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=0.286/15.519
=0.01842902

BioSig Technologies's asset turnover of this year was 0.00437956. BioSig Technologies's asset turnover of last year was 0.01842902. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+1+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

BioSig Technologies has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

BioSig Technologies  (NAS:BSGM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


BioSig Technologies Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of BioSig Technologies's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


BioSig Technologies (BioSig Technologies) Business Description

Traded in Other Exchanges
N/A
Address
55 Greens Farms Road, 1st Floor, Westport, CT, USA, 06880
BioSig Technologies Inc is a commercial stage medical device company. It is developing a proprietary technology platform to minimize noise and artifacts from cardiac recordings during electrophysiology studies and ablation.
Executives
Kenneth L Londoner director, 10 percent owner 10 RED COAT ROAD, WESTPORT CT 06880
Steven J Buhaly officer: Chief Financial Officer 1195 NW LOMPTON DRIVE, BEAVESTON OR 97006
John Sieckhaus officer: Chief Operating Officer C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880
Steve Chaussy officer: Chief Financial Officer 9780 E AVE, HESPERIA CA 92345
Patrick Joseph Gallagher director 275 PLEASANT HILL RD., FLANDERS NJ 07836
Gray Fleming officer: Chief Commercial Officer C/O BIOSIG TECHNOLOGIES, INC., 55 GREENS FARMS ROAD, WESTPORT CT 06880
James L Klein director 2300NE BROOKWOOD PKWY, HILLSBORO OR 97124
Frederick Hrkac director C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880
James J Barry director C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV L3 6744832
Jeffrey F Odonnell director 126 ROSSMORE DRIVE, MALVERN PA 19355
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Martha Pease director 33 SEAVIEW, MADISON CT 06443
John M Kowalski officer: VP of Sales 54 WILTON ROAD, 2ND FLOOR, WESTPORT CT 06880
Samuel E Navarro director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044